Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer

摘要: Abstract Purpose: To evaluate the efficacy of single-agent gefitinib (Iressa, ZD1839), an oral, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, as first-line compassionate use therapy for advanced non-small-cell lung cancer (NSCLC). Patients and methods: Twenty-five patients who were unfit or refused chemotherapy received oral 250mg daily treatment recurrent metastatic NSCLC in a program at single institution. Results: Four 22 evaluable (18%), two with adenocarcinomas bronchioloalveolar carcinomas, had objective response five (23%) stable disease. Duration disease was 3.5–22+ months. Median time to progression 2.2 months, median survival 12.6 months 1-year 52%. The partial plus rate by Eastern Cooperative Oncology Group (ECOG) performance status (PS) 4/5 PS 0 patients; 3/6 1–2 2/14 3–4 patients. PS>2 derived benefit from 3 due co-morbidities. Two discontinued severe toxicities: one patient liver dysfunction hemorrhagic cystitis, another developed diarrhea hypotension. A correlation between rash antitumor activity noted. Of seven subsequent gefitinib, response, three disease, progressed, non-evaluable response. Conclusion: We report encouraging results unselected NSCLC. Gefitinib monotherapy should undergo further evaluation